AstraZeneca to buy biotech Neogene for up to $320m
29th Nov 2022 07:12
(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy biotechnology group Neogene for up to $320m, as it looks to accelerate its ambition in oncology cell therapy.
Read moreThree AstraZeneca drugs recommended for EU approval
14th Nov 2022 07:22
(Sharecast News) - AstraZeneca announced on Monday morning that three of its drugs had been recommended for approval in the European Union.
Read moreAstraZeneca's Imfinzi gets FDA approval for lung cancer treatment
11th Nov 2022 07:27
(Sharecast News) - AstraZeneca on Friday said its Imfinzi drug in combination with the Imjudo antibody and platinum-based chemotherapy has been approved in the US for the treatment of adult patients with stage IV non-small cell lung cancer.
Read moreAstraZeneca lifts full-year earnings guidance after strong Q3
10th Nov 2022 08:27
(Sharecast News) - AstraZeneca lifted its full-year earnings guidance on Thursday following a solid third quarter.
Read moreFDA committee votes in favour of AstraZeneca asthma candidate
9th Nov 2022 08:25
(Sharecast News) - AstraZeneca announced on Wednesday that a US Food and Drug Administration (FDA) committee has voted in favour of an adult asthma treatment.
Read moreAstrazeneca's Beyfortus receives EU approval
4th Nov 2022 07:02
(Sharecast News) - Drugmaker AstraZeneca said on Friday that its Beyfortus asset had received European Union approval for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants.
Read moreAstraZeneca breast cancer drug shows 'significant' improvement in trial
26th Oct 2022 07:56
(Sharecast News) - AstraZeneca said its capivasertib breast cancer drug combined with Faslodex hormone treatment demonstrated a "statistically significant and clinically meaningful improvement" in progression-free patient (PFS) survival during a late-stage trial.
Read moreAstraZeneca says Fasenra fails to meet one trial endpoint
25th Oct 2022 07:51
(Sharecast News) - AstraZeneca said its Fasenra treatment for a rare inflammatory disease of the oesophagus failed to meet one of the two dual-primary endpoints in a phase 3 trial.
Read moreAstraZenenca liver cancer combination treatment approved by FDA
24th Oct 2022 07:19
(Sharecast News) - AstraZeneca said its Imjudo drug, in combination with Imfinzi, hadbeen approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer, the company said on Monday.
Read moreJapan green lights AstraZeneca asthma drug
27th Sep 2022 08:28
(Sharecast News) - AstraZeneca drug Tezspire has been approved for use with patients with severe asthma in Japan, the blue chip confirmed on Tuesday.
Read moreAstraZeneca's gMG treatment receives EU approval
23rd Sep 2022 07:27
(Sharecast News) - Drugmaker AstraZeneca said on Friday that Ultomiris, its long-acting C5 inhibitor, had received EU approval to be used in the treatment of adult patients with generalised myasthenia gravis, a rare autoimmune neuromuscular disease.
Read moreAstraZeneca's severe asthma treatment gets EU approval
21st Sep 2022 07:05
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that Tezspire, its severe asthma treatment, had received EU approval for use as an add-on maintenance treatment in patients 12 years and older.
Read moreAstraZeneca's Covid-19 antibody combination receives EU approval
20th Sep 2022 07:46
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that Evusheld, its long-acting antibody combination, had been granted approval for the treatment of adults and adolescents with Covid-19 in the European Union.
Read moreAstraZeneca blod clot treatment meets trial endpoint
16th Sep 2022 07:28
(Sharecast News) - AstraZeneca on Friday said its Danicopan add-on anti blood-clotting drug had met a primary endpoint in a phase III trial.
Read moreAstraZeneca, Sanofi respiratory drug gets EU marketing go-ahead
16th Sep 2022 07:02
(Sharecast News) - AstraZeneca and Sanofi said their Beyfortus drug for the prevention of lower respiratory tract disease in newborns and infants has been recommended for marketing authorisation in the European Union
Read more